Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026)
Johnson & Johnson (JNJ) posted Cash from Operations of 8616000000.0 for Q2 2026, up 242.72% sequentially from 2514000000.0 in Q1 2026, and up 122.18% YoY from 3878000000.0 in Q2 2025.
Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Cash from Operations for 18 years, with the latest figure at 8616000000.0 in Q2 2026.
- Quarterly Cash from Operations rose 122.18% year-over-year to 8616000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 27608000000.0 (up 19.89% YoY) and the FY2025 annual result came in at 24530000000.0, up 1.09% from the prior year.
- Cash from Operations rose to 8616000000.0 in Q2 2026 per JNJ's latest filing, from 2514000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 9169000000.0 in Q3 2025 and troughed at 2514000000.0 in Q1 2026.
- A 5-year average of 5638250000.0 and a median of 4907500000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2026: Cash from Operations soared 123.63% in 2023, then slumped 39.77% in 2026.
- Over 5 years, Cash from Operations stood at 3979000000.0 in 2022, then surged by 97.61% to 7863000000.0 in 2023, then dropped by 11.19% to 6983000000.0 in 2024, then rose by 4.67% to 7309000000.0 in 2025, then grew by 17.88% to 8616000000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 8616000000.0, 2514000000.0, and 7309000000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 8.62 Bn |
| Jun 28, 2026 | 8.62 Bn |
| Mar 29, 2026 | 2.51 Bn |
| Mar 29, 2026 | 2.51 Bn |
| Dec 28, 2025 | 7.31 Bn |
| Dec 28, 2025 | 7.31 Bn |
| Sep 28, 2025 | 9.17 Bn |
| Sep 28, 2025 | 9.17 Bn |
| Jun 29, 2025 | 3.88 Bn |
| Jun 29, 2025 | 3.88 Bn |
| Mar 30, 2025 | 4.17 Bn |
| Mar 30, 2025 | 4.17 Bn |
| Dec 29, 2024 | 6.98 Bn |
| Dec 29, 2024 | 6.98 Bn |
| Sep 29, 2024 | 7.99 Bn |
| Sep 29, 2024 | 7.99 Bn |
| Jun 30, 2024 | 5.63 Bn |
| Jun 30, 2024 | 5.63 Bn |
| Mar 31, 2024 | 3.66 Bn |
| Mar 31, 2024 | 3.66 Bn |